Skip to main content
OpenTrials
Completed

NCT Number: NCT03402828

Body PSOriasis: Long-term Relapse CONTROL

This non-interventional study of real-life clinical practice strategies for long-term relapse control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from 60-100 Russian dermatology sites and follow the patients for up to 52 weeks. The study will map actual strategies and focus on patients' and dermatologists' experience with the different topicals used, including unspecified products with and without active drugs.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Vulgaris

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The State Autonomous Foundation of Public Health "Republic Clinical Dermatovenereological Dispensary" of the Republic of Tatarstan

Kazan', Tatarstan Republic, 420012, Russia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients planned to receive topical treatment of any kind to prevent relapse of symptoms
  • Written informed consent

Exclusion criteria

  • Contraindications to selected treatment
  • Ongoing systemic treatment of psoriasis with steroids, anti-inflammatory drugs or phototherapy

Treatment and study plan

Any topical drug treatment

Drug

Any treatment strategy used to prevent relapse of psoriasis symptoms

Other names: Non-drug topicals

Primary outcomes

  1. Time of relapse

    Time frame: Up to 52 weeks

    Length of relapse free period after start of maintenance strategy

Secondary outcomes

  1. Dermatology Life Quality Index

    Time frame: Up to 52 weeks

    Standard QoL measure within dermatology

  2. PGA (physician's global assessment of symptoms)

    Time frame: Up to 52 weeks

    5-point verbal rating scale

  3. PsGA (patient's global assessment of symptoms)

    Time frame: Up to 52 weeks

    5-point verbal rating scale

Sponsors and collaborators

Lead sponsor

LEO Pharma

Industry

Registry information

Official study title

Body PSOriasis: Long-term Relapse Control in Patients With Psoriasis Vulgaris in Daily Clinical Practice of Russian Dermatologists.

Acronym: PSO-CONTROL

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Jan 18, 2018
Registry last updated
Mar 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.